Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

    NEXT STORY
    Shire plc : Shire Announces Sale of Oncology Business to Servier for $2.4 Billion
    PREV STORY
    Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    $29.5 Billion Big Pharma Outlook to 2026

    Dublin, Nov. 08, 2017 (GLOBE NEWSWIRE) -- The "Big Pharma Outlook 2026" report has ...

    author_avatar
    NASDAQ Market News

    Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic

    author_avatar
    NASDAQ Market News

    Agios Reports Business Highlights and Third Quarter 2019 Financial Results

    author_avatar
    NASDAQ Market News